Seattle Nurse Practitioner Busted: DEA Revokes Controlled Substance License
Published Date: 6/26/2025
Notice
Summary
Scott Hansen, a nurse practitioner from Seattle, had his DEA registration suspended and is losing his license to handle controlled substances because he kept prescribing drugs after his state license was suspended. Since he didn’t ask for a hearing, the DEA decided to revoke his registration to keep the public safe. This means he can no longer legally prescribe or handle controlled substances, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Scott Hansen
Scott Hansen's DEA Certificate of Registration No. MH7100124 is revoked, so he can no longer legally prescribe, dispense, or handle controlled substances. The Order takes effect on July 28, 2025.
Pending and Future Washington Registrations Denied
The Order also denies any pending applications by Scott Hansen to renew or modify this DEA registration and denies any other pending applications for additional registration in Washington. That denial is effective July 28, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-11730 — Agency Information Collection Activities; Notice and Request for Comment; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery
NHTSA wants your thoughts on how they collect feedback about their services. They’re asking for approval to keep gathering this info in a simple, easy way that helps them improve. If you use or interact with their services, this could affect you, and they’re open for comments now before they get the green light.
Next: 2025-11732 — Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing of Proposed Rule Change To List and Trade Shares of the Sprott Physical Copper Trust
NYSE Arca wants to start trading shares of the Sprott Physical Copper Trust, letting investors buy and sell copper-backed units easily. This change affects anyone interested in investing in copper through the stock market and could open new ways to invest starting soon after approval. It’s a fresh, shiny chance to add copper to your portfolio with the convenience of regular stock trading.